BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12096492)

  • 1. [Primary subcutaneous mantle cell lymphoma treated successfully with THP-COP therapy].
    Hisatake J; Kawakami K; Nakamaki T; Hino K; Tomoyasu S
    Rinsho Ketsueki; 2002 May; 43(5):384-8. PubMed ID: 12096492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
    Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
    J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment approaches for mantle-cell lymphoma.
    Witzig TE
    J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
    Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
    Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
    J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cure by THP-COP therapy in patients with perforated T-cell type malignant lymphoma of the jejunum].
    Kajiura Y; Ogoshi K; Nakamura K; Miyaji M; Kondo Y; Makuuchi H; Tajima T; Oobayashi Y; Masumoto A; Horiki T; Suzuki T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):413-7. PubMed ID: 9492837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
    Hanamura A; Hayakawa M; Naito K
    Rinsho Ketsueki; 2005 Jan; 46(1):13-8. PubMed ID: 16708912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Granulocytic sarcoma developing in lymph nodes].
    Watanabe I; Yakushijin Y; Sakai I; Yasukawa M; Fujita S
    Rinsho Ketsueki; 2002 May; 43(5):378-83. PubMed ID: 12096491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma in the ocular adnexal region.
    Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
    Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report.
    Yoo SB; Kim YA; Jeon YK; Kim CW
    Pathol Res Pract; 2008; 204(10):779-83. PubMed ID: 18572329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
    Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
    van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
    Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mantle cell lymphoma with skin invasion characterized by the common variant in the subcutis and blastoid transformation in the overlying dermis.
    Ishibashi M; Yamamoto K; Kudo S; Chen KR
    Am J Dermatopathol; 2010 Apr; 32(2):180-2. PubMed ID: 20010283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of deferred initial therapy in mantle-cell lymphoma.
    Martin P; Chadburn A; Christos P; Weil K; Furman RR; Ruan J; Elstrom R; Niesvizky R; Ely S; Diliberto M; Melnick A; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
    J Clin Oncol; 2009 Mar; 27(8):1209-13. PubMed ID: 19188674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.
    Eve HE; Furtado MV; Hamon MD; Rule SA
    J Clin Oncol; 2009 Nov; 27(32):e189-90; author reply e191. PubMed ID: 19805667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.